Why Big Pharma Can't Innovate — The Cultural Bottleneck Exposed

What we talked about.

In this episode of The Sunny Ray Show, host Sunny Ray sits down with Haidar, founder of the brand tech firm Kaidu and the venture capital firm Allegory Capital, to trace an unusual path from childhood coding on hand me down computers to reshaping how pharmaceutical companies innovate. Haidar explains how early freelance web development, open source WordPress work, and a master's degree rooted in Kaizen and Six Sigma shaped a systems driven mindset that he later applied to chaotic marketing and brand functions inside regulated industries. He discusses his time bridging marketing and pharma giants like Novartis and Novo Nordisk at Accenture, the frustrations that pushed him to found Kaidu in 2012, and why he later launched Allegory Capital in 2022 to invest directly in digital health startups rather than simply advise. The conversation closes on why big pharma, despite massive innovation budgets, struggles to move at startup speed and why culture, not technology, remains the real bottleneck to transformation.

A Kaizen minded founder explains why culture, not technology, is the real reason big pharma can't innovate fast.

The questions, and the answers.

What first pulled you into programming and what were you building as a teenager?

My dad brought home old computers from his job at Mars, and they came with books on Fortran, Cobol, and Pascal. I didn't even know it was called coding, I just mixed the computers together and followed the recipes in the books. That's how I discovered the web, moving from HTML to PHP in the early web developer era before DevOps existed.

You were freelancing in web development at 16 and later worked on open source WordPress projects, is that right?

Yes, a group of friends and I realized people wanted a corner of the internet, so we started building the first shops and sites. We ended up forming a small agency in eastern France, and our first clients were politicians. I was one of the first in my area doing pure performance based SEO, where you only paid if you ranked first on Google.

How did your master's in industrial management, rooted in Kaizen and Lean Six Sigma, shape the way you later approached branding?

That background was an inflection point for me. I saw systematic Six Sigma thinking everywhere, from clean water to airplanes, and I noticed a huge gap between the structured engineering world and the chaotic world of marketing and communications. I realized you could build a system to help a brand scale and position messaging correctly across many countries, the same way engineering controls quality.

What surprised you most about the pharmaceutical industry when you first entered it through Accenture?

Pharma is unusually open to outside help compared to banking or insurance, which stay very inhouse. Coming from automotive, the quality systems and SOPs weren't a surprise. What shocked me was how slow commercial operations move, it's a check the box culture without the data driven mindset you'd expect from an industry built on clinical data.

What was the specific frustration that made you launch Kaidu instead of continuing to climb the corporate ladder?

I felt ready to pursue my real purpose, transforming regulated industries. Working inside another firm means bending to someone else's chain of command and politics. I understood that if you know how the industry works, you can become an agent of change from outside, so I started the firm with clients who told me they would follow if I launched it.

What gap in the market did Kaidu fill by positioning itself as a brand tech firm rather than a pure agency or consultancy?

Consulting firms sell strategy to the C suite but leave delivery to cheap agencies, while operational agencies can't scale across 50 different specialties for one client. We built teams that go from strategy to delivery, placing our own people on our payroll for a year or two before transferring them to the client, passing on our culture and methodology in the process.

After a decade building Kaidu, what led you to launch Allegory Capital as a venture capital arm in 2022?

Clients kept asking us to help modernize teams shifting from legacy molecules to new launches, and eventually asked for tech driven service innovation too. Pharma companies don't have the culture to build tech products internally, so I proposed investing in the outside innovation ecosystem instead, the same way pharma already invests in biotech, but applied to digital health across a global portfolio.

Why can't big pharma innovate at the speed of tech, and is this a teaser for a future conversation?

Pharma spends huge amounts on innovation, but it is iterative, planning for challenges over 20 to 100 years. Tech innovation is disruptive, chaotic, and captured in three to six month windows. Pharma isn't culturally wired to move that fast, which is why it looks like a sleeping giant, and why people like me try to build a middleware between fast tech innovation and pharma's slower, reassurance driven pace.